8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – May 5, 2006

________________________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

_____________________

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

610-594-3319

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On May 5, 2006, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that the Company will conduct a live webcast of its Investor Day event on Wednesday, May 10, 2006 from 1:00 p.m. to approximately 3:00 p.m. EDT. The event will be held at the Grand Hyatt Hotel in New York, New York. The following members of management will be presenting at the event:

Donald Morel, Chairman and Chief Executive Officer

Steven Ellers, President and Chief Operating Officer

William Federici, Vice President and Chief Financial Officer

Robert Hargesheimer, President, Tech Group

Donald McMillan, President Americas Region, Pharmaceutical Systems

John Paproski, Vice President, Innovation

Michael Schaefers, Director of Marketing, Europe

Mike Anderson, Vice President and Treasurer

A copy of the Company’s presentation from the Investor Day will be available through the Investor link at the Company’s website, http://www.westpharma.com and is also attached hereto as Exhibit 99.1. A copy of the press release is attached hereto as Exhibit 99.2. Both Exhibits are incorporated herein by reference.

The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statement and Exhibits

(d)	Exhibits
	Exhibit #	Description
	99.1	West Pharmaceutical Services, Inc. presentation slides.
	99.2	West Pharmaceutical Services, Inc. Press Release, dated May 5, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

May 10, 2006

EX-99

Donald E. Morel, Jr., Ph.D.

Chairman & Chief Executive Officer

Agenda

Don MorelWelcome

Steve EllersGlobal Operations Overview

Mike SchaefersPharma Systems Marketing

Don McMillanSelective Product Overview

Bob Hargesheimer Tech Group

John PaproskiInnovation Engine

Bill FedericiFinancial Overview

All ParticipantsQ&A

Certain statements contained in this presentation and certain statements that may be made by management of the Company orally during
this presentation are forward-looking statements that set forth anticipated results based on management’s plans and assumptions.  Such
statements give our current expectations or forecasts of future events – they do not relate strictly to historical or current facts. In
particular, these include statements concerning future actions, future performance or results of current and anticipated products, sales
efforts, expenses, the outcome of contingencies such as legal proceedings and financial results. We have tried, wherever possible, to
identify such statements by using words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and
terms of similar meaning in connection with any discussion of future operating or financial performance or condition.   

We cannot guarantee that any forward-looking statement will be realized. If known or unknown risks or uncertainties materialize, or if
underlying assumptions are inaccurate, actual results could differ materially from past results and those expressed or implied in any
forward-looking statement.  You should bear this in mind as you consider forward-looking statements. We cannot predict or identify all
such risks and uncertainties, but factors that could cause the actual results to differ materially from expected and historical results
include the following:  sales demand; timing and commercial success of customers’ products incorporating our products and services,
including specifically, the Exubera® Inhalation-Powder insulin device; our ability to pass raw-material cost increases on to customers
through price increases; maintaining or improving production efficiencies and overhead absorption; constraints on manufacturing
capacity in the face of anticipated demand; the availability of labor to meet increased demand; competition from other providers; the
successful integration of acquired businesses; average profitability, or mix, of products sold in a reporting period; financial performance
of unconsolidated affiliates; strength of the U.S. dollar in relation to other currencies, particularly the Euro, UK Pound, Danish Krone,
Japanese Yen and Singapore Dollar; interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the
availability of raw materials and key bought-in components; raw-material price escalation, particularly petroleum-based raw materials,
and energy costs; and availability and pricing of materials that may be affected by vendor concerns with exposure to product-related
liability.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised, however, to
consult any further disclosures the Company makes on related subjects in the Company's 10-K, 10-Q and 8-K reports.

Safe Harbor Statement

Who are we?

Each and every day

millions of West
products are used to
enhance healthcare
around the world.

Corporate Profile

World's premier manufacturer of
components and systems for
injectable drug delivery

Stoppers and seals for vials

Disposable components
used in syringe, IV, blood
collection and diagnostic
systems

Founded in 1923

HQ in Lionville, PA

2005 sales $700M

Market capitalization $1.2 Billion

Diverse Customer Base

Company Estimated Market Share: 70% in Pharma; 70% in Device; 95% in Biotech

32 manufacturing sites

34 sales offices

7 technical centers

6,000 employees worldwide

Global Presence

Key Company Developments

Acquisition of Monarch Laboratories

Acquisition of The Tech Group

Acquisition of Medimop

Sale of GFI Clinical Unit

Sale of Contract Manufacturing Operations

New management team

Restructuring and increased CAPEX

Sale of OTC Research Services Group

Kinston plant accident

Kinston restart

2-for-1 stock split

Divestiture of Drug Delivery

FY 2005

FY 2004

FY 2003

FY 2002

FY 2001

FY05 Net sales: Approx. $700 MM

Business Segments

Geographic Sales Mix(2005, based on point of sale)

Corporate Growth Strategy
Core Pharmaceutical Systems Business

Maximize the value of West’s core business   
(Company estimated market:  $1.1 BN)

Market segmentation

Generate maximum value from key growth drivers

New product innovation

Lean manufacturing

Geographic expansion

Strategic acquisitions

Medimop Medical Projects Ltd.

Corporate Growth Strategy
Tech Group Business

Build market share in multi-component systems
for drug delivery

(Company estimated market:  $4.5 BN)

Leverage customer base

Develop a portfolio of proprietary systems for injectable,
transmucosal, and pulmonary delivery

Pursue selected consumer opportunities

License or acquire innovative technologies

Pursue strategic acquisitions

The Tech Group

Diabetes

Components

for Pen System Applications

Components for

Traditional System
Applications

Devices

West’s Competitive Edge

Unmatched experience/expertise: drug material
interface

Ability to source components from multiple
locations globally

Protected IP: West’s components and systems

Regulatory barrier to entry:  NDA and ANDA
filing must include reference to all
packaging/components in contact with the drug:

1.

West Drug Master File (DMF) 1546 is confidential

2.

West DMF includes functionality data (multi-year studies)

3.

All primary package changes require new stability/ functionality
studies for new filing

Investment Considerations

Established platform for sustainable growth

Significant barriers to entry

Favorable growth drivers in key market
segments

Global, diverse customer base

Global manufacturing capability

Strong, experienced management team

Strong corporate governance

Steve Ellers

President & Chief Operating Officer

Overview

Organization

Financial performance

Strategic initiatives

Manufacturing strategy

Product launch process

President and Chief Operating Officer

Business Units with P/L

North America

South America

Europe and Asia Pacific

The Tech Group

Reconstitution (Medimop)

Global Headquarters

Global Supply Chain

& Support Services

Strategic Business

Development

Innovation

2005 Performance

Record sales and profits

Completed three acquisitions

Better positioned for profitable growth

Stronger position with customers

Improved product pipeline

Innovation launched

Drivers for Improved Financial Performance

Returned focus to core injectable business

Reorganized to regional business units

Faster response time to market

Better coordination of resources

Significant increase in CAPEX

Better quality

Greater capacity

Improved efficiencies

Faster response time to market

Value creation

Success with Lean Sigma

Sales Performance

CAGR = 12%

Operating Profit Performance

Note:  2004 operating profit excludes $11.6M of business interruption and out-of-pocket  

          costs related to the 2003 Kinston accident.

CAGR = 15%

Consolidated Capital Expenditures

Capital as % of sales 12%             9%      12%        11%            8%

Depreciation as % of sales   8%     8%        6%          6%            7%

Key Initiatives For Growth

Market segmentation

Product launches

Accelerate innovation

Lean Sigma initiatives

Expand capacity to meet growing demand

Market Segmentation Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Market Segment Growth Drivers

Biotechnology/Oncology

Diabetes

Prefillable Syringes

Reconstitution Systems

FluroTec^® and BarrierCoatings

Westar^®
Processing

West Spectra^TM

Market Segment Growth Drivers

Biotechnology/Oncology

Diabetes

Prefillable Syringes

Reconstitution Systems

Components for

Traditional System
Applications

Components

for Pen System Applications

Market Segment Growth Drivers

Biotechnology/Oncology

Diabetes

Prefillable Syringes

Reconstitution Systems

Market Segment Growth Drivers

Biotechnology/Oncology

Diabetes

Prefillable Syringes

Reconstitution Systems

Market Segmentation Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Manufacturing Philosophy

Centers of Excellence – Focused Factories

Pharmaceutical

Device

Cellular Manufacturing

Zero Defect

Vision inspection

Six Sigma

Multiple site sourcing

Managed as cost centers

Manufacturing Processes

Rubber

Compounding          Molding   Trimming    Finishing

Specialty products

Metal

TrimTec^®

Compounding

Molding

Trimming

Washing

Metals

TrimTec^®

Market Segmentation Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Consolidated Capital Expenditures

Capital as % of sales 12%             9%      12%        11%            8%

Depreciation as % of sales   8%     8%        6%          6%            7%

Market Segmentation Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Product Launch Process

Match need in market with West product

Target specific customers

Secure development partnerships

Sampling

Machine trials

Stability tests

Regulatory assistance

Analytical Labs

Product Launch Process

Plan – Initiate Launch Campaign

CAPEX investments

Promotion

Training

Sample kits

Broad market - product launch (2 - 3 years later)

Market experience

Market acceptance

Customer ramp-ups

Product Launches

Westar^® RS

Elastomer components

Seals

Westar^® Units Sold
(in millions)

Product Launches

Drive development through superior positioning

Investor Day May 10, 2006

FluroTec^®

Unrivaled

barrier

coating

Westar^®

State of the art
ready-to-sterilize
elastomer
closures

Flip-Off^® CCS™

Prewashed and
sterilized
Flip-Off seals

West Spectra™

Covert and overt
security for product
authentication

Key Trends

Growth Drivers

Global demographics – Diabetes

Biotechnology – Oncology, prefilled syringe systems and reconstitution

Anti-counterfeiting needs

Growing demand for capital

Lead market

Add value to customers

Grow faster than market

Cross sell West capabilities

Pharma Systems

Tech

Medimop

Innovation

Innovation creating new markets

Summary

Grow faster than market

Fund CAPEX investments

Accelerate innovation activities:

In house R&D

Licensing

Strategic partnering

Acquisitions

Expand geographically

Synergies from cross selling

Mike Schaefers, Ph.D.

Director of Marketing Europe

Marketing Initiatives

  Sustainable above-market growth through:

Global key account management

Marketing initiatives for key growth products

Market segmentation strategy

New product launches / pre-launch activities

Innovations

Global Key Account Management

Based upon well trained and experienced Key
Account Managers

Integrates West’s well-known Technical Support
function into customer relationship

Coordinates all activities between customers and
West globally using the Diamond approach

Global Key Account Management – cont.

Marketing

TCS

Regulatory

Operations

QA

R&D

Information

Systems

Investing  for Sustainable Growth

Investor Day May 10, 2006

Key Account

Coordination

Supplier

Development

Supplier

Customer

Marketing

Regulatory

Operations

QA

R&D

Information

Systems

Global Key Account Management

Ensures usage of Value Selling / Value Capture

Generates long-term supply agreements

Establishes strategic partnerships with customers

Marketing Initiatives for Growth Products

Product positioning and branding

Focused communication

Sales campaigns

Liaison with opinion leaders, authorities

Marketing Initiatives for Growth Products

Drive development through superior positioning

Investing for Sustainable Growth

Investor Day May 10, 2006

FluroTec^®

Unrivaled

barrier

coating

Westar^®

State of the art
ready to sterilize
elastomer
closures

Flip-Off^® CCS™

Prewashed and
sterilized
Flip-Off seals

West Spectra™

Cover and overt
security for product
authentication

Communication

Develop new, global state-of-the-art web site with links to
key products

Generate and publish product specific articles around key
growth products

Issue ads for key growth products

Exhibit and lecture at key conferences and congresses
globally

Marketing Initiatives For Growth Products

Sales Campaigns

Develop and execute sales campaigns to increase product
awareness and knowledge of customers through:

Mailing to targeted customers

Product specific brochures

Product specific sample kits

Product specific customer presentations

Educational Series

Technical seminars & roadshows

Marketing Initiatives For Growth Products

Strengthen product positioning through liaison with:

Opinion leaders

Professional organizations (i.e. PDA, AAPS )

Regulatory bodies (i.e. FDA, EMEA)

Marketing Initiatives For Growth Products

Implement

Develop

Focus

Market Segmentation Strategy

Analyze market trends and customer needs

Focus development on key segments

Develop segment plans through dedicated, cross-functional
teams

Implement segment specific market plans

Analyze

Investor Day May 10, 2006

Investing for Sustainable Growth

Market Segmentation Strategy

Key growth segments – delivery systems

Prefilled syringes

Medical devices

Key growth segments – markets

Vaccines

Diabetes

Biopharmaceuticals

Generics

Market Segmentation Strategy

Concentrate company and marketing resources
based upon specific market plan i.e.:

Technical Support

Material Sciences

Business Development Manager

Regulatory Affairs

Segment specific sales and communication tools i.e.:

Biotech Sample Kit

Biotech Web Site

Product Launches

Promote reconstitution
and transfer systems
(Medimop)

Clip´n´Ject

Vial Adapter

Mix2Vial

MixJect

Investing for Sustainable Growth

Investor Day May 10, 2006

Product Launches

Prefilled syringe
component offerings

Complete range of
FluroTec plungers from
0.5 ml to 10 ml

Global launch of new,
´state of the art´
Thermoset Formula for
Needle Shields and Tip
Caps  

Launch FluroTec Tip Cap
into market

Investing for Sustainable Growth

Investor Day May 10, 2006

Six Sigma Quality Product

Meeting customer demand for enhanced quality products

100 % inspected

Low particulate matter

Low protein contamination

Product Launches

Summary

  Sustainable above-market growth through:

Global key account management

Marketing initiatives for key growth products

Market segmentation strategy

New product launches / pre-launch activities

Innovations

Don McMillan

President, North America

Pharmaceutical Systems Division

Pharmaceutical and Biotech Market

Pharmaceutical Market

West has strong position for packaging components

Low single digit growth rates

Focusing on Biotech to strengthen their pipelines

Partnership, acquisitions and alliances

Biotech Market

CAGR 15% (2003 – 2008)

High value products

Sensitive proteins and peptides

Targets for counterfeit drugs

Predominately injectable products

West products are low percentage of COGS

West enjoys “partnership” relationships

Many emerging companies

West’s focus on the Biotech Market

Value drivers

Drug product efficacy

Management of risk

Patient convenience and compliance

Product R&D driven by the needs of the Biotech market

Proprietary products

Value added products drive growth in excess of volume

Incorporate advanced technologies

Barrier coatings for elastomers

Westar processing of elastomers

Clinical to commercial standardization

Compliant with latest regulatory requirements and standards

Customized products for anti-counterfeit protection

West FluroTec

Westar

Product Evolution to Combat Drug Counterfeiting

Permission granted by Amgen, Inc.

West’s standard product

2^nd generation product

3^rd generation product

2^nd generation product

The Next Generation Products

Package authentication with overt and covert technologies

Item level serialization for electronic track and trace

Emerging Biotech

Many small companies focused on bringing new therapies to
market

West has an opportunity to:

Educate the market

Share regulatory and packaging science expertise

Dedicated Emerging Biotech team

Consultative selling process

Tailor products to their specific needs

Laboratory services

Packaging components

Introduce next generation products and services

Customers’ Product Development Cycle

Laboratory Services

Delivery/Device Systems

Packaging Components

Traditional West Interface:

Packaging Components

West’s Evolving Interface:

Phase III

Commercialization

Phase II

Phase 1

Conclusion

Existing relationships with major players

Dedicated effort for emerging companies

Broad line of existing proprietary products and
services

Biotech market needs drive product R&D

Leverage market knowledge to identify and introduce
additional value added products and services  

Bob Hargesheimer

President, The Tech Group

Custom injection molding and assembly services

focused on OEM customers in the

consumer and health care markets.

Investing for Sustainable Growth

Acquired by West, May 2005

The Tech Group

FY04 Sales: $74.2 MM

Consumer
24%

Health Care 76%

West Device Group

FY04 Sales: $65.0 MM

Health Care
30%

Consumer 70%

The Tech Group Offerings

Custom contract-manufacturing services

Precision plastic injection-molding and assembly

Expertise in product design, including in-house mold
design and construction

Automated assembly solutions

Quick-response center for developmental and
prototype tooling

Markets

Health Care

Consumer

Customer Base

Health Care

Device

Consumer

Internationally Positioned

12 manufacturing facilities

1,900 employees

887,000 square feet for manufacturing

The Tech Group Growth Strategy

Market leadership through technical
excellence.

Design services

Regulatory expertise

Analytical lab services

Tooling

High volume assembly

Six Sigma support

The Tech Group Growth Strategy

Build share in multi-component systems.

Leverage relationships and experience.

Add value with West experience/capabilities.

Technology support for proprietary systems.

Pursue select Consumer opportunities.

Technology based advantage.

Health Care Market Segments

Pharmaceutical Delivery

Surgical/Medical Device

Health Care Market Segments

Diagnostic

Other

The Tech Group Growth Strategy

Build share in multi-component systems.

Leverage relationships and experience.

Add value with West
experience/capabilities.

Technology support for proprietary
systems.

Pursue select Consumer opportunities.

Technology based advantage.

Consumer

Summary

Continued growth through:

Building share in multi-component systems

Pursue selected consumer opportunities

Focus on key services

Leverage West and Tech capabilities

Execute on product pipeline

Investing for Sustainable Growth

John Paproski

Vice President of Innovation

Focus On Growth: Historical View

Drug Development Division was a focal point

Formulation and Nasal Based Delivery Systems -- exited in  2005

Plastic Division (now Tech Group) added new processing technologies

State-of-art molding technologies

Clean room molding

High speed assembly

Market the capability as a custom molder

Core Injectable business focused on value-added features to
proprietary products

Daikyo technologies and Japanese Quality

Westar

Coatings

Seals

Prefilled syringe components

Focus On Growth: Historical View: R&D

Global Engineering and Product Development

Product design and development

Tooling design and construction

Elastomer material development

Design and construction of assembly and processing equipment

Develop new packaging and device concepts

# of  Employees: 64 professionals in these activities.

Segment Expenditures

200520042003

Pharma Systems $6.3 MM$5.2 MM $4.6 MM

Tech Group $1.6 MM $1.6 MM $1.7 MM

Innovation at West: Stepping It Up

Refocused on proprietary products for injectable
drug packaging and delivery systems

Increased innovation spending an additional $4-6M in
2006

Multiple technology license/agreements acquired

Increased I.P. activity

Prototype thru scale up developments

Medimop acquisition

Established an innovation process and group

Innovation at West: The Process

Required Elements for Innovation Success

1.

Market need

2.

Customer access

Current Focus: The Pharmaceutical Market

3.

West core competency

Injectable technical expertise and support

Global manufacturing capability in metal, rubber,
plastic and assembly

GMP and GLP capabilities

Creative injectable product developer

4.

Technology match

Injectable Pharma Market Trends

Sustained new biotech NME’s

Frequent lyophilized NME’s

Prefilled syringe growth

Self administration

Patient/clinician convenience as a differentiator

Simplify pharma filling and processing

Needle safety

Counterfeit concerns

Long acting drug formulations

Innovation at West: Importance of Injectables
NME & BLA Approvals (FDA)

Source:  The Pink Sheet; FDA Website

39

40

35

31

26

40

31

20

Therapeutic Areas

Anti-Infectives

Biologicals

Cardiovascular

Diabetes Therapy

Hormones

Immunology

Neurology

Oncology

Ophthalmology

Osteoporosis

Market Trends

Pre Filled Syringe Growth

Self Administration

Abundant Biotech NME’s

Frequent Lyophilized NME’s

Needle Safety

Patient/Clinician Convenience as a
Differentiator

Simplify Pharma Filling and Processing

Long Acting Drug Formulations

Counterfeit Concerns

Therapeutic

Categories

Pharma Market

Trends

The Reconstitution Product Category: Market Drivers

Lyophilized NME’s

Necessity for stability

Self administration

Caregiver convenience: a pharma product differentiator

Reconstitution Supplies

Remove Flip Off™

From Diluent Vial

Remove Flip Off™

From Drug Vial

Alcohol Swab

Stopper Surface

Remove Needle Cover

Prepare Syringe

Draw Air Into Syringe

Prepare for

Dilluent Withdrawl

Insert Syringe into

Vial Stopper

Push Air into Vial

Withdraw Dilluent

From Vial

Adjust Dose in Syringe

Withdraw Syringe

from Vial

Insert Syringe into

Drug Vial

Inject Liquid Into

Drug Vial

Unmixed Solution

Dispose of Syringe

Mix Solution

Insure Mixing is Complete

Swab the top of

the Drug Vial

Prepare the Injection Syringe

Draw air into the

Injection Syringe

Push air into the Vial

Invert Vial

Carefully

Position

Needle

Draw Contents from Vial

Ready for Injection

The Reconstitution Product Category

Innovation at West:  Portfolio Building

West’s Traditional Products

Clip’n’Ject

Medimop

Targeting Innovation

ALIGN

PRODUCT CATEGORY WITH    MARKET TRENDS

Vial Projects

Component Projects

To Be Announced

To Be Announced

Reconstitution

Counterfeiting

Pharma
Processing

   Caregiver

Convenience

Caregiver

   Safety

Lyo NME’s

Biotech NME’s

Self Admin.

PFS Growth

Inj. Pharma

Market

Trends

Product

Category

Innovation at West:

Growing New Product Portfolio

Expansion within the product category

Spin-off products

Evolutionary path within the category

Follow-up product generations

Supporting products

New categories

Focused and manageable injectable projects

Future non injectable

Cross category

Innovation Summary

Best pipeline of products in recent history

Offerings will:

Relate directly to customers and markets we now serve

Leverage the combined capabilities and customer access
that exist in our:

Divisions

Partners

Recently acquired businesses

William FedericiChief Financial Officer

Investing for Sustainable Growth

   .12

-

-

-

-

-

Interest Payment

$.54*

$1.40

$1.33

$1.32

   $.96

$.83

EPS Non-GAAP

-

-

(.02)

-

-

-

Affiliate Gain

-

-

    .30

(.42)

-

-

Kinston

-

-

-

-

(.03)

-

Foreign Currency

   (.01)

   .05

(.07)

-

(.09)

-

Unusual Tax
Items

-

(.04)

    .03

    .26

   .30

  .05

Restructuring

$0.43

$1.39

$1.09

$1.48

$.78

$.78

EPS Reported

Q1 2006

2005

2004

2003

2002

2001

GAAP/Non-GAAP Reconciliation

* Included in 2006 full-year non GAAP EPS guidance of $1.68 – $1.78.

This information is being provided for the convenience of readers in making comparisons between the periods presented
and other periods

Consolidated Sales and Non-GAAP EPS
from Continuing Operations
($ in millions)

First Quarter Results
($ in millions, except per share data)

$0.41

$0.43

E.P.S. from Continuing Operations

$0.41

$0.54

Non-GAAP E.P.S. from Continuing Operations

$13.0

$14.3

Income from Continuing Operations

$20.1

$28.2

Operating Profit

$25.2

$38.0

Selling, General & Administrative Expenses

    31%

30%

Gross Margin

  $149.5

$222.8

Net Sales

2005

2006

2006 E.P.S. from continuing operations includes a $0.12 charge related to the refinancing of senior
notes and a $0.01 favorable impact related to an IRS tax claim settlement.

Capital Management

$118.7

$133.5

Working Capital

          $11.4

      YTD Spending

Capital Expenditures:

45.0%

42.3%

     Debt to Total Invested Capital

$625.0

$640.6

Total Capitalization

$281.0

$271.0

Total Debt

12/31/05

3/31/06

($M)

Gross Margin Percentages

Corporate Cash Flow
($ in millions)

Corporate Cash Flow is defined as operating cash flow less capital expenditures and dividends.

Debt Maturity Schedule
($ in millions)

$0

Debt to Total Capitalization

Goal: 40-45% excluding acquisitions and significant capital expansion

In Summary

Strong cash flow from operations

Strong balance sheet

Foundation is in place to fund future growth

Focus on cost control and lean initiatives

Donald E. Morel, Jr., Ph.D.

Chairman & Chief Executive Officer

Summary

West has a set of competitive advantages that
uniquely position the company for future growth

These competitive advantages capitalize on the
primary growth drivers in key market segments

Global, diverse customer base

Solid financial base

Strong, experienced management team focused
on execution